Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 22, Issue 1-2, 1996, Pages 131-135

  Zinzani, P L ^a,b   Zompatori, M ^a   Bendandi, M ^a   Battista, G ^a   Fanti, S ^a   Barbieri, E ^a   Gherlinzoni, F ^a   Rimondi, M R ^a   Frezza, G ^a   Pisi, P ^a   Merla, E ^a   Gozzetti, A ^a   Canini, R ^a   Monetti, N ^a   Babini, L ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bulky mediastinal disease; CT scan; Gallium 67; Lymphoma; MRI

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; GALLIUM CITRATE GA 67;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE; FIBROSIS; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEDIASTINUM MASS; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; RADIODIAGNOSIS; TREATMENT OUTCOME;

EID: 15844395239     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609051740     Document Type: Article

References (37)

1. Jochelson, M., Mauch, P., Balikian, J., Rosenthal, D., Canellos, G. (1985) The significance of the residual mediastinal mass in treated Hodgkin's disease. J. Clin. Oncol., 3, 634-640.
2. Khoury, M. B., Godwin, J. D., Halvorsen, R. et al. (1986) Role of the chest CT in non-Hodgkin lymphoma. Radiology, 158, 659-662.
3. Radford, J. A., Cowan, R. A., Flanagan, M. et al. (1988) The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J. Clin. Oncol., 6, 940-946.
4. Klimo, P., Connors, J. M. (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Intern. Med., 102, 596-602.
5. Fisher, R. I., Gaynor, E. R., Dahlberg, S. et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med., 328, 1002-1006.
6. Mazza, P., Zinzani, P. L., Martelli, M. et al. (1995) MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Leuk. Lymphoma, (In Press). 16, 657-663, 20(314): 1995.
7. Mazza, P., Zinzani, P. L., Martelli, M. et al. (1995) MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Leuk. Lymphoma, (In Press). 16, 657-663, 20(314): 1995.
8. Tura, S., Mazza, P., Gherlinzoni, F. et al. (1986) High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma. Scand. J. Haematol., 37, 347-352.
9. Canellos, G. P., Nadler, L., Takvorian, T. (1988) Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. Semin. Hematol., 25 (suppl 2), 58-65.
10. Gherlinzoni, F., Martelli, M., Mazza, P. et al. (1994) Autologous bone marrow transplantation (ABMT) vs DHAP in aggressive non-Hodgkin's lymphomas (NHL) partially responding to first-line chemotherapy. Blood, 84 (suppl 1), 234a.
11. Zinzani, P. L., Mazza, P., Gherlinzoni, F. et al. (1992) Massive mediastinal involvement in stage I-II Hodgkin's disease: response to combined modality treatment Leuk. Lymphoma, 8, 81-85.
12. Tura, S., Canellos, G. P., Goldstone, A. et al. (1991) Hodgkin's disease: controversies and challenges for the future. Haemalologica, 76, 63-79.
13. Longo, D. L., Russo, A., Duffey, P. L. et al. (1991) Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case of combined modality treatment. J. Clin. Oncol., 9, 227-235.
14. The International non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. (1993) N. Engl. J. Med., 329, 987-994.
15. Lewis, E., Bemardino, M. E., Salvador, P. G. et al. (1982) Post therapy CT detected mass in lymphoma patients. Is it viable tissue? J. Comput. Assist. Tomogr., 6, 792-796.
16. Russell, K. J., Hoppe, R. T. (1989) Response of mediastinal Hodgkin's disease to radiotherapy: rate of tumor regression not predictive of outcome. Int. J. Radiat. Oncol. Biol. Phys., 16, 201-204.
17. Canellos, G. P. (1988) Residual mass in lymphoma may not be residual disease. J. Clin. Oncol., 6, 931-933.
18. Kaplan, W. D., Jochelson, M. S., Herman, T. S. et al. (1990) Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J. Clin. Oncol., 8, 1966-1970.
19. Front, D., Israel, O., Epelbaum, R. et al. (1990) Ga-67 SPECT before and after treatment of lymphoma. Radiology, 175, 515-519.
20. Front, D., Ben-Haim, S., Israel, O. et al. (1992) Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology, 182, 359-363.
21. Cooper, D. L., Caride, V. J., Zloty, M., Germino, J., Farber, L. R., Hoffer, P. B. (1993) Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy. J. Clin. Oncol., 11, 1092-1098.
22. King, S. C., Reiman, R. J., Prosnitz, L. R. (1994) Prognostic importance of restaging Gallium scans following induction chemotherapy for advanced Hodgkin's disease. J Clin. Oncol., 12, 306-311.
23. Janicek, M., Kaplan, W., Neuberg, D., Canellos, G. P., Shulman, L., Shipp, M. A. (1994) Early restaging Gallium scans identify durable responses to induction therapy in high risk patients with aggressive non-Hodgkin's lymphoma (NHL). Blood, 84, (suppl 1), 233a.
24. Nyman, R. S., Rehn, S. M., Glimelius, B. L. G., Hagberg, H. E., Hemmingsson, A. L., Jung, B. (1987) Magnetic resonance imaging for assessment of treatment effects in mediastinal Hodgkin's disease. Acta Radiologica, 28, 145-151.
25. Nyman, R. S., Rehn, S. M., Glimelius, B. L. G., Hagberg, H. E., Hemmingsoon, A. L., Sundstrom, C. J. (1989) Residual mediastinal masses in Hodgkin's disease: prediction of size with MR imaging. Radiology, 170, 435-440.
26. Tesoro-Tess, J. D., Balzarini, L., Ceglia, E., Petrillo, R., Santoro, A., Musumeci, R. (1991) Magnetic resonance imaging in the initial staging of Hodgkin's disease and non-Hodgkin lymphoma. Eur. J. Radiol., 12, 81-90.
27. Rahmouni, A., Tempany, C., Jones, R., Mann, R., Yang, A., Zerhouni, E. (1993) Lymphoma: monitoring tumor size and signal intensity with MR imaging. Radiology, 188, 445-451.
28. Gasparini, M. D., Balzarini, L., Castellani, M. R. et al. (1993) Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer, 72, 577-582.
29. Hill, M., Cunningham, D., MacVicar, D. et al. (1993) Role of magnetic resonance imaging in predicting relapse residual masses after treatment of lymphoma. J. Clin. Oncol., 11, 2273-2278.
30. 67Gallium scan in mediastinal malignant lymphoma: a retrospective pilot study. Ann. Oncol., 5, 433-436.
31. Stansfeld, A. G., Diebold, J., Kapanci, Y. et al. (1988) Updated Kiel classification for lymphomas. Lancet, i, 292-293.
32. Oken, M., Creech, R., Tormey, D. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5, 649-655.
33. Bonadonna, G., Zucali, R., De Lena, M., Valagussa, P. (1977) Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Cancer Treat. Rep., 61, 769-777.
34. Guglielmi, C., Amadori, S., Anselmo, A. P. et al. (1987) Sequential combination chemotherapy of high grade non-Hodgkin's lymphoma with 5-fluoouracil, methotrexale, cytosine-arabinoside, cy lophosphamide, doxorubicin, vincristine and prednisone (F-MACHOP). Cancer Invest., 5, 159-169.
35. Zinzani, P. L., Barbieri, E., Visani, G. et al. (1994) Ifosfamide, epirubicin, and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica, 79, 508-512.
36. Wahl, R. L., Quint, L. E., Cieslak, R. D., Aisen, A. M., Koeppe, R. A., Meyer, C. R. (1993) Anatometabolic tumor imaging: fusion of FDG-PET with CT or MRI to localize foci of increased activity. J. Nucl. Med., 34, 1190-1197.
37. Newman, J. S., Francis, I. R., Kaminski, M. S., Wahl, R. L. (1994) Imaging of lymphoma with PET with 2-(F-18)-Fluoro-2-deoxy-D-glucose: correlation with CT. Radiology, 190, 111-116.